Literature DB >> 19067525

Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.

Lijun Wang1, Jiyun Shi, Young-Seung Kim, Shizhen Zhai, Bing Jia, Huiyun Zhao, Zhaofei Liu, Fan Wang, Xiaoyuan Chen, Shuang Liu.   

Abstract

This report describes the synthesis of two cyclic RGD (Arg-Gly-Asp) conjugates, HYNIC-2PEG(4)-dimer (HYNIC = 6-hydrazinonicotinyl; 2PEG(4)-dimer = E[PEG(4)-c(RGDfK)](2); and PEG(4) = 15-amino-4,7,10,13-tetraoxapentadecanoic acid) and HYNIC-3PEG(4)-dimer (3PEG(4)-dimer = PEG(4)-E[PEG(4)-c(RGDfK)](2)), and evaluation of their (99m)Tc complexes [(99m)Tc(HYNIC-2PEG(4)-dimer)(tricine)(TPPTS)] ((99m)Tc-2PEG(4)-dimer: TPPTS = trisodium triphenylphosphine-3,3',3''-trisulfonate) and [(99m)Tc(HYNIC-3PEG(4)-dimer)(tricine)(TPPTS)] ((99m)Tc-3PEG(4)-dimer) as novel radiotracers for imaging integrin alpha(v)beta(3) expression in athymic nude mice bearing U87MG glioma and MDA-MB-435 breast cancer xenografts. The integrin alpha(v)beta(3) binding affinities of RGD peptides were determined by competitive displacement of (125)I-c(RGDyK) on U87MG glioma cells. It was found that the two PEG(4) linkers between RGD motifs in HYNIC-2PEG(4)-dimer (IC(50) = 2.8 +/- 0.5 nM) and HYNIC-3PEG(4)-dimer (IC(50) = 2.4 +/- 0.7 nM) are responsible for their higher integrin alpha(v)beta(3) binding affinity than that of HYNIC-PEG(4)-dimer (PEG(4)-dimer = PEG(4)-E[c(RGDfK)](2); IC(50) = 7.5 +/- 2.3 nM). Addition of extra PEG(4) linker in HYNIC-3PEG(4)-dimer has little impact on integrin alpha(v)beta(3) binding affinity. (99m)Tc-2PEG(4)-dimer and (99m)Tc-3PEG(4)-dimer were prepared in high yield with >95% radiochemical purity and the specific activity of >10 Ci/mumol. Biodistribution studies clearly demonstrated that PEG(4) linkers are particularly useful for improving the tumor uptake and clearance kinetics of (99m)Tc-2PEG(4)-dimer and (99m)Tc-3PEG(4)-dimer from noncancerous organs. It was also found that there was a linear relationship between the tumor size and radiotracer tumor uptake expressed as %ID (percentage of the injected dose) in U87MG glioma and MDA-MB-435 breast tumor models. The blocking experiment showed that the tumor uptake of (99m)Tc-2PEG(4)-dimer is integrin alpha(v)beta(3)-mediated. In the metabolism study, (99m)Tc-2PEG(4)-dimer had high metabolic stability during its excretion from renal and hepatobiliary routes. (99m)Tc-3PEG(4)-dimer also remained intact during thee excretion from the renal route, but, had approximately 30% metabolism during the excretion from the hepatobiliary route. Planar imaging studies in U87MG glioma and MDA-MB-435 breast tumor models showed that the tumors of approximately 5 mm in diameter could be readily visualized with excellent contrast. Thus, (99m)Tc-3PEG(4)-dimer is a very promising radiotracer for the early detection of integrin alpha(v)beta(3)-positive tumors, and may have the potential for noninvasive monitoring of tumor growth or treatment efficacy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19067525      PMCID: PMC2634825          DOI: 10.1021/mp800150r

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  64 in total

1.  99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.

Authors:  S Liu; D S Edwards
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.

Authors:  R Haubner; H J Wester; U Reuning; R Senekowitsch-Schmidtke; B Diefenbach; H Kessler; G Stöcklin; M Schwaiger
Journal:  J Nucl Med       Date:  1999-06       Impact factor: 10.057

3.  microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.

Authors:  Yun Wu; Xianzhong Zhang; Zhengming Xiong; Zhen Cheng; Darrell R Fisher; Shuang Liu; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

Review 4.  Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors.

Authors:  V W van Hinsbergh; A Collen; P Koolwijk
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

Review 5.  Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging.

Authors:  Shuang Liu
Journal:  Mol Pharm       Date:  2006 Sep-Oct       Impact factor: 4.939

Review 6.  Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging.

Authors:  Christophe Van De Wiele; Ruth Oltenfreiter; Olivier De Winter; Alberto Signore; Guido Slegers; Rudi Andre Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-22       Impact factor: 9.236

7.  MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides.

Authors:  Xiaoyuan Chen; Shuang Liu; Yingping Hou; Michel Tohme; Ryan Park; James R Bading; Peter S Conti
Journal:  Mol Imaging Biol       Date:  2004 Sep-Oct       Impact factor: 3.488

8.  18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis.

Authors:  Xiaoyuan Chen; Ryan Park; Anthony H Shahinian; Michel Tohme; Vazgen Khankaldyyan; Mohammed H Bozorgzadeh; James R Bading; Rex Moats; Walter E Laug; Peter S Conti
Journal:  Nucl Med Biol       Date:  2004-02       Impact factor: 2.408

Review 9.  Multimodality imaging of tumor integrin alphavbeta3 expression.

Authors:  Xiaoyuan Chen
Journal:  Mini Rev Med Chem       Date:  2006-02       Impact factor: 3.862

10.  Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer.

Authors:  Shuang Liu; Wen-Yuan Hsieh; Young Jiang; Young-Seung Kim; Subramanya G Sreerama; Xiaoyuan Chen; Bing Jia; Fan Wang
Journal:  Bioconjug Chem       Date:  2007-03-07       Impact factor: 4.774

View more
  58 in total

1.  Binding and transport of PAMAM-RGD in a tumor spheroid model: the effect of RGD targeting ligand density.

Authors:  Carolyn L Waite; Charles M Roth
Journal:  Biotechnol Bioeng       Date:  2011-07-19       Impact factor: 4.530

2.  Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.

Authors:  Mark P Borgman; Omer Aras; Sandra Geyser-Stoops; Edward A Sausville; Hamidreza Ghandehari
Journal:  Mol Pharm       Date:  2009 Nov-Dec       Impact factor: 4.939

3.  Evaluation of 99mTc-labeled cyclic RGD dimers: impact of cyclic RGD peptides and 99mTc chelates on biological properties.

Authors:  Yang Zhou; Young-Seung Kim; Xin Lu; Shuang Liu
Journal:  Bioconjug Chem       Date:  2012-03-06       Impact factor: 4.774

4.  Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.

Authors:  Sudipta Chakraborty; Jiyun Shi; Young-Seung Kim; Yang Zhou; Bing Jia; Fan Wang; Shuang Liu
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

5.  Comparison of biological properties of 99mTc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging.

Authors:  Zuo-Quan Zhao; Yong Yang; Wei Fang; Shuang Liu
Journal:  Nucl Med Biol       Date:  2016-02-27       Impact factor: 2.408

6.  Towards continuous-to-continuous 3D imaging in the real world.

Authors:  L Caucci; Z Liu; A K Jha; H Han; L R Furenlid; H H Barrett
Journal:  Phys Med Biol       Date:  2019-09-18       Impact factor: 3.609

7.  Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers.

Authors:  Zhaofei Liu; Shuanglong Liu; Fan Wang; Shuang Liu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-19       Impact factor: 9.236

8.  2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics.

Authors:  Jiyun Shi; Young-Seung Kim; Sudipta Chakraborty; Bing Jia; Fan Wang; Shuang Liu
Journal:  Bioconjug Chem       Date:  2009-07-15       Impact factor: 4.774

9.  Evaluation of K(HYNIC)(2) as a bifunctional chelator for (99m)Tc-labeling of small biomolecules.

Authors:  Shundong Ji; Yang Zhou; Guoqiang Shao; Shuang Liu
Journal:  Bioconjug Chem       Date:  2013-04-08       Impact factor: 4.774

Review 10.  Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency.

Authors:  Shuang Liu
Journal:  Bioconjug Chem       Date:  2009-12       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.